Kurt A. Gustafson

2012 - Halozyme Therapeutics

In 2012, Kurt A. Gustafson earned a total compensation of $1.9M as Former Vice President and Chief Financial Officer at Halozyme Therapeutics, a 147% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$47,454
Option Awards$318,540
Salary$372,186
Stock Awards$1,120,770
Other$7,888
Total$1,866,838

Gustafson received $1.1M in stock awards, accounting for 60% of the total pay in 2012.

Gustafson also received $47.5K in non-equity incentive plan, $318.5K in option awards, $372.2K in salary and $7.9K in other compensation.

Rankings

In 2012, Kurt A. Gustafson's compensation ranked 3,813th out of 11,487 executives tracked by ExecPay. In other words, Gustafson earned more than 66.8% of executives.

ClassificationRankingPercentile
All
3,813
out of 11,487
67th
Division
Manufacturing
1,326
out of 4,253
69th
Major group
Chemicals And Allied Products
296
out of 1,198
75th
Industry group
Drugs
175
out of 920
81st
Industry
Biological Products, Except Diagnostic Substances
33
out of 160
79th
Source: SEC filing on April 7, 2014.

Gustafson's colleagues

We found five more compensation records of executives who worked with Kurt A. Gustafson at Halozyme Therapeutics in 2012.

2012

Gregory Frost

Halozyme Therapeutics

Chief Executive Officer

2012

H Shepard

Halozyme Therapeutics

Chief Scientific Officer

2012

James Shaffer

Halozyme Therapeutics

Former Vice President and Chief Commercial Officer

2012

Jean Liu

Halozyme Therapeutics

General Counsel

2012

David Ramsay

Halozyme Therapeutics

Chief Financial Officer

News

You may also like